Abstracts
national drug codes (NDC). RESULTS: Risedronate accounted for 27% of all bisphosphonates prescriptions while alendronate accounted for the vast majority of bisphosphonate prescriptions with approximately 70% of the market over the [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] timeframe. Both alendronate and risedronate together accounted for approximately 92% of all reimbursements for both oral and injectable bisphosphonates during the study period. Alendronate's market share, as measured by total reimbursement, has been steadily declining from third quarter of 2004 to the third quarter of 2007, accounting for approximately 57% of total reimbursements, contrary to the roughly 83% of all reimbursements from the fourth quarter of 1996 to the second quarter of 2004. CONCLUSIONS: Market share for the leading brand drugs has steadily declined with the introduction of generic competition as measured by overall utilization and total reimbursement, such as risedronate competing with alendronate in the bisphosphonate market and raloxifene competing with calcitonin-salmon in the alternative osteoporosis market. Examination of the Medicaid data also revealed a strident market shift in utilization following the fourth quarter of 2005, resulting from the switching of dual eligibles from Medicaid to Medicare Part D. To compare the traditionally used approach for fracture risk assessment in cost-effectiveness analysis (CEA) compared to the use of FRAX models based on multiple individual clinical risk factors (CRFs) using the osteoporosis treatment bazedoxifene. METHODS: In CEA of osteoporosis the fracture risk has traditionally been calculated with risk-adjustments based on age, bone mineral density (BMD) and prior fracture. The treatment effect has been derived from clinical trials and the same effi cacy has been assumed irrespective of the fracture risk of the population. A novel approach to fracture risk assessment considers the contribution of 8 individual CRFs on fracture risk and mortality using the FRAX -tool. The application of FRAX to clinical trial populations has shown that treatment effi cacy increases with higher fracture risk. The cost-effectiveness was estimated in a Markov cohort model with US data using a health care perspective. The CEA compared the osteoporosis treatment bazedoxifene (BZA) to no treatment in women with a T-score for femoral neck BMD of 2.5SD and previous fracture. Using the old approach BZA was set to reduce the risk of vertebral fracture by 42% based on the overall analysis of the phase III study. Using the FRAX -approach the vertebral fracture risk reduction varied depending on pre-hoc fracture probability in the target population and was estimated at 59%. The relative risk of a vertebral fracture compared to the general population was 3.96 and 1.82 with the old and FRAX -approach, respectively. RESULTS: The cost per QALY gained with bazedoxifene treatment was estimated at $54,712 using the old approach and $33,650 using the FRAX -approach. This is due to differences in the assessment of fracture risk effi cacy, fracture risk and mortality.
PMS20 A COMPARISON OF DIFFERENT METHODS OF ESTIMATING FRACTURE RISK AND FRACTURE RISK REDUCTION IN COST-EFFECTIVENESS ANALYSES OF THE OSTEOPOROSIS TREATMENT BAZEDOXIFENE

CONCLUSIONS:
The advent of more accurate assessment of fracture risk assessment and its use as a determinant of effi cacy has important consequences for CEA. Knee osteoarthrosis is a multifactorial, progressive and incurable rheumatic ailment; most treatments look for a maximum recovery of mobility and functionality of the knee joint, with a minimum risk possibility. Due to its high cost and invasive character, gonarthrosis surgical treatment is reserved, according to the clinical practice guidance available in Mexico, for severe pain and joint functionality limitation cases; defi ned as knee osteoarthrosis present in IV degree, or functional class III onwards. This study evaluates cost and effectiveness of the use of Hylan G-F 20 vs. intraarticular steroids to withhold surgery in patients with severe knee osteoarthrosis. METHODS: Cost-effectiveness analysis using a decision tree to simulate a hypothetical cohort behavior of patients with severe knee osteoarthrosis for a period of two years, from the perspective of the health service supplier. Costs were estimated using prices of 2008 and are expressed in US dollars (exchange rate of 11.14 pesos/ 1 US dollar). RESULTS: With Hylan G-F 20, 94.6% of patients did not require surgery during the analysis period vs. 50%, in the case of those under intraarticular steroid treatment. Expected treatment costs: Hylan G-F 20, $2081.0, and intraarticular steroids, $4593.2. The average cost-effectiveness of treatments: Hylan G-F 20, $2200.5 and intraarticular steroids, $9111.6. Incremental analysis shows Hylan G-F 20 as dominant alternative. Different sensitivity analyses corroborate the dominance relationship exercised by Hylan G-F 20 over the steroid treatment. CONCLUSIONS: Hylan G-F 20 is a more effective and less expensive alternative than steroid treatment to withhold surgery in patients with severe knee osteoarthrosis.
PMS21 ECONOMIC EVALUATION OF THE USE OF HYLAN G-F 20 IN THE HANDLING OF SEVERE KNEE OSTEOARTHROSIS
PMS22 COST-EFFECTIVENESS OF THE USE OF ETANERCEPT VS. RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN MEXICO
Gao X 1 , Hwang S 2 , Carpiuc KT 1 , Stephens JM 1 , Sato R 2 , Singh A 2 , Rivera R 3 , García E 3 , Bierschwale H 3 1 PharMerit North America LLC, Bethesda, MD, USA, 2 Wyeth Research, Collegeville, PA, USA, 3 Wyeth Mexico, Naucalpan, Mexico, Mexico OBJECTIVES: To determine the cost-effectiveness of etanercept plus methotrexate (MTX) versus rituximab plus MTX in the treatment of rheumatoid arthritis (RA) patients from a payer's perspective in Mexico. METHODS: A literature-based decision analytic model was developed to compare the cost and effectiveness of etanercept 25 mg twice-weekly MTX versus rituximab 2 500 mg infusion MTX and rituximab 2 1000 mg infusion MTX (labeled dosage) in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs. The primary measure of clinical outcomes was based on remission (Disease Activity Score 28 joint count 2.6). The model incorporated major and minor infectious events, discontinuation due to inadequate effi cacy or adverse event, and rituximab re-treatment within the one year timehorizon. Data from clinical trials (TEMPO and SERENE) were used. Drug and resource-use costs were based on government-reported public costs. Sensitivity analysis was conducted by varying effi cacy and cost parameters by 30%. RESULTS: The annual total therapy cost for rituximab was MEX$74,543 (2 500 mg) and MEX$137,223 (2 1000 mg), and MEX$119,133 for etanercept. The incremental cost-effectiveness ratio (ICER) of etanercept vs. rituximab 2 500 mg was MEX$201,581 per additional patient achieving remission. Etanercept was cost saving compared to rituximab 2 1000 mg. With a hypothetical budget of MEX$10,000,000 for rituximab or etanercept, the number of patients achieving remission would be 7 (2 500 mg) and 4 (2 1000 mg) for rituximab and 23 for etanercept. Sensitivity analysis showed that etanercept continued to have more patients achieving remission than rituximab (for both dosage forms) even if drug cost and effi cacy were varied 30%, given a defi ned budget. CONCLUSIONS: The results suggest that etanercept appears to be cost-effective compared to rituximab. For the labeled and commonly used rituximab dosage (2 1000 mg), etanercept appears to be a cost-saving alternative. These fi ndings were robust for plausible ranges of effectiveness and drug acquisition costs.
